Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial

Published in:

Journal of the European Academy of Dermatology & Venereology, 2022, v. 36, n. 4, p. e277, doi. 10.1111/jdv.17836

By:

• Ryan, C.;
• Guenther, L.;
• Foley, P.;
• Weisman, J.;
• Burge, R.T.;
• Gallo, G.;
• See, K.;
• McKean‐Matthews, M.;
• Bertram, C.C.;
• Merola, J.F.

Publication type:

Article